Premium
Changes in serum calcium and vitamin D 3 levels after tibolone treatment and their correlations with health‐related quality of life
Author(s) -
Bhattacharya Sudhindra M.,
Ghosh Mainak
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2014.08.010
Subject(s) - medicine , tibolone , vitamin d and neurology , quality of life (healthcare) , body mass index , group b , prospective cohort study , menopause , calcium , vitamin , gastroenterology , nursing
Objective To assess the effects of tibolone on serum calcium and vitamin D 3 levels, the effects on health‐related quality of life (HRQOL), and the relationship between these variables. Methods An open‐label, prospective, parallel‐arm study was conducted at S.C. Das Memorial Medical and Research Center, Kolkata, India, between July 2012, and June 2013. Women aged 34–55 years were eligible when they were experiencing surgical menopause and were symptomatic. Group A comprised patients who chose to receive tibolone (2.5 mg daily for 6 months) and group B comprised those who refused treatment. At baseline and 6 months, body mass index (BMI), serum calcium and vitamin D 3 levels and HRQOL were assessed. Results Of 79 participants, 53 were in group A and 26 in group B. After 6 months, BMI had increased significantly in both groups. The vitamin D 3 level had increased significantly from baseline in group A ( P = 0.02), and was higher than that in group B ( P = 0.01). HRQOL had also improved significantly from baseline in group A ( P = 0.001), and was significantly better than that in group B ( P < 0.001). In group A, a significant correlation was found between HRQOL improvement and vitamin D 3 levels ( P < 0.001). Conclusion Tibolone significantly increases the serum vitamin D 3 level and improves HRQOL in menopausal women. Clinical Trial Registry India: CTRI/2012/06/002752.